N@N

Facet Biotech: Facet Biotech Names Ted Llana, Ph.D. Senior Vice President, Commercial and Corporate Development

^{Published on 2009-01-12 07:55:25, Last Modified on 2009-01-12 07:56:02 - Market Wire}
 

REDWOOD CITY, CA--(Marketwire - January 12, 2009) - Facet Biotech Corporation (NASDAQ: [ FACT ]) today announced the appointment of Ted Llana, Ph.D. as Senior Vice President, Commercial and Corporate Development, of the company. Dr. Llana will be responsible for leading the company's corporate development, business development and new product planning activities.

"Ted is a key addition to our senior leadership team, as he brings a tremendous amount of strategic business experience and solid scientific skills to the organization," said Faheem Hasnain, president and chief executive officer of Facet Biotech. "We are looking forward to his contributions in helping to shape Facet into a promising new biotech company."

From September 2001 to November 2008, Dr. Llana held various positions of increasing responsibility at Biogen Idec Inc., including most recently as Vice President, Oncology/Rheumatology Strategic Business Unit. In his most recent role at Biogen Idec, he defined and executed the strategy to grow and progress Biogen Idec's oncology and rheumatology pipelines and managed Biogen Idec's Rituxan® collaboration with Genentech, Inc. Prior to working in the oncology business unit, Dr. Llana headed up corporate strategy at Biogen Idec and led global marketing at Biogen. Dr. Llana's prior business experience includes serving as a partner at Documedics, Inc. and as a Vice President at Covance, Inc. where he provided strategic consulting on product commercialization and marketing in the pharmaceutical, biotechnology and medical device industries. Dr. Llana began his career as a Biologist at the National Cancer Institute. He received his Ph.D. in Cellular Immunology from Cornell University and his MBA from Georgetown.

About Facet Biotech

Facet Biotech is a biotechnology company dedicated to advancing its pipeline of four clinical-stage products and leveraging its research and development capabilities to identify and develop new drugs. Facet Biotech Corporation launched in December 2008 as a spin-off from PDL BioPharma, Inc.

NOTE: Facet Biotech and the Facet Biotech logo are considered trademarks of Facet Biotech Corporation. Rituxan is a registered trademark of Biogen Idec Inc.